The latest price and purchase methods of Lifitegrast in 2025

Lifitegrast (Lifitegrast) is an eye drop specifically indicated to treat the symptoms of dry eye disease (DED) in adults 17 years of age and older. The drug was approved by the U.S. Food and Drug Administration (FDA) on July 11, 2016, becoming an effective option on the market to treat dry eye syndrome.

Ritalast's mechanism of action is relatively unique. It mainly works by preventing a protein called lymphocyte function-associated antigen-1 (LFA-1) on the surface of leukocytes from binding to the ICAM-1 adhesion molecule. ICAM-1 is overexpressed in the cornea and conjunctival tissue of dry eye patients, and the interaction between LFA-1 and ICAM-1 is closely related to the activation and migration of T cells and the secretion of inflammatory cytokines. By blocking this important interaction, Ritalast reduces the release of inflammatory cytokines, thereby improving dry eye symptoms. Although its specific mechanism of action is not yet fully understood, its efficacy has been confirmed in clinical trials.

Regarding the price and purchase channels of Litalast, the original drug has not yet been launched in China, so the specific price and medical insurance-related information are still unclear. However, in overseas markets, the specifications of the original version of Litalast are usually 5% concentration, 50 mg/mL, and are packaged in 60 tubes. Each box may be sold for more than 700 US dollars. This price is a considerable burden for many patients who need to use the drug for a long time.

In addition to the original drug, some generic versions of Ritalast have also emerged on the market. The ingredients of these generic drugs are basically the same as those of the original drugs. For example, the specifications produced by Indian pharmaceutical factories are 5% W/V, 3 mL, and each box sells for about 200 yuan. Generic drugs are increasingly favored by patients due to their lower prices and similar effects. However, when choosing generic drugs, consumers should ensure that they come from legitimate sources to avoid purchasing substandard products.

Reference materials:https://go.drugbank.com/drugs/DB11611